piracetam has been researched along with Canine Diseases in 8 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Minimum plasma levetiracetam concentration can be reached after rectal administration of 40 mg/kg in dogs affected by cluster seizures and status epilepticus and concurrently receiving other antiepileptic drugs." | 9.27 | Pharmacokinetics of rectal levetiracetam as add-on treatment in dogs affected by cluster seizures or status epilepticus. ( Amedeo, S; Bertone, I; Cagnotti, G; D'Angelo, A; Dappiano, E; Gardini, G; Guerriero, G; Lentini, L; Odore, R, 2018) |
| "To evaluate the efficacy and tolerability of levetiracetam monotherapy in dogs with structural epilepsy." | 7.85 | Levetiracetam monotherapy for treatment of structural epilepsy in dogs: 19 cases (2010-2015). ( Kelly, D; Raimondi, F; Shihab, N, 2017) |
| " There are multiple retrospective studies reporting good efficacy and tolerability of the anti-epileptic drug levetiracetam (LEV) in human patients with epilepsy; however, reports of LEV's tolerability and efficacy in dogs with epilepsy remain limited." | 7.81 | Assessment into the usage of levetiracetam in a canine epilepsy clinic. ( Nye, G; Packer, RM; Porter, SE; Volk, HA, 2015) |
| "Five phenobarbital treated dogs were classified as true responders (≥50% reduction in seizures/month) whereas none of the levetiracetam treated dogs fulfilled this criterion." | 6.82 | A single-blinded phenobarbital-controlled trial of levetiracetam as mono-therapy in dogs with newly diagnosed epilepsy. ( Berendt, M; Fredsø, N; Møller, A; Sabers, A; Toft, N, 2016) |
| "Minimum plasma levetiracetam concentration can be reached after rectal administration of 40 mg/kg in dogs affected by cluster seizures and status epilepticus and concurrently receiving other antiepileptic drugs." | 5.27 | Pharmacokinetics of rectal levetiracetam as add-on treatment in dogs affected by cluster seizures or status epilepticus. ( Amedeo, S; Bertone, I; Cagnotti, G; D'Angelo, A; Dappiano, E; Gardini, G; Guerriero, G; Lentini, L; Odore, R, 2018) |
| " Repeat video-EEG 2 months after initiation of levetiracetam treatment disclosed a >95% decrease in frequency of myoclonic seizures, and absence seizures were no longer evident." | 3.88 | Absence Seizures as a Feature of Juvenile Myoclonic Epilepsy in Rhodesian Ridgeback Dogs. ( Cortez, MA; Fischer, A; James, FMK; Kluger, G; Lohi, H; Neßler, JN; Tipold, A; Wielaender, F, 2018) |
| "To evaluate the efficacy and tolerability of levetiracetam monotherapy in dogs with structural epilepsy." | 3.85 | Levetiracetam monotherapy for treatment of structural epilepsy in dogs: 19 cases (2010-2015). ( Kelly, D; Raimondi, F; Shihab, N, 2017) |
| " The dog was receiving levetiracetam and phenobarbital for epilepsy, and serum concentrations of both were within standard therapeutic ranges." | 3.85 | Suspected Phenobarbital-Induced Pseudolymphoma in a Dog. ( Lampe, R; Manens, J; Sharp, N, 2017) |
| " There are multiple retrospective studies reporting good efficacy and tolerability of the anti-epileptic drug levetiracetam (LEV) in human patients with epilepsy; however, reports of LEV's tolerability and efficacy in dogs with epilepsy remain limited." | 3.81 | Assessment into the usage of levetiracetam in a canine epilepsy clinic. ( Nye, G; Packer, RM; Porter, SE; Volk, HA, 2015) |
| "Twenty-two dogs with idiopathic epilepsy which were pharmacoresistant to phenobarbitone and bromide were treated with levetiracetam as an add-on medication." | 3.74 | The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs. ( Chandler, KE; Luján Feliu-Pascual, A; Matiasek, LA; Platt, SR; Volk, HA, 2008) |
| "Five phenobarbital treated dogs were classified as true responders (≥50% reduction in seizures/month) whereas none of the levetiracetam treated dogs fulfilled this criterion." | 2.82 | A single-blinded phenobarbital-controlled trial of levetiracetam as mono-therapy in dogs with newly diagnosed epilepsy. ( Berendt, M; Fredsø, N; Møller, A; Sabers, A; Toft, N, 2016) |
| "To describe a serious adverse event as a result of rapid intravenous injection of undiluted levetiracetam in a dog." | 1.48 | A serious adverse event secondary to rapid intravenous levetiracetam injection in a dog. ( Bacek, LM; Biddick, AA; Taylor, AR, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kelly, D | 1 |
| Raimondi, F | 1 |
| Shihab, N | 1 |
| Lampe, R | 1 |
| Manens, J | 1 |
| Sharp, N | 1 |
| Wielaender, F | 1 |
| James, FMK | 1 |
| Cortez, MA | 1 |
| Kluger, G | 1 |
| Neßler, JN | 1 |
| Tipold, A | 1 |
| Lohi, H | 1 |
| Fischer, A | 1 |
| Biddick, AA | 1 |
| Bacek, LM | 1 |
| Taylor, AR | 1 |
| Cagnotti, G | 1 |
| Odore, R | 1 |
| Gardini, G | 1 |
| Amedeo, S | 1 |
| Bertone, I | 1 |
| Guerriero, G | 1 |
| Lentini, L | 1 |
| Dappiano, E | 1 |
| D'Angelo, A | 1 |
| Packer, RM | 1 |
| Nye, G | 1 |
| Porter, SE | 1 |
| Volk, HA | 2 |
| Fredsø, N | 1 |
| Sabers, A | 1 |
| Toft, N | 1 |
| Møller, A | 1 |
| Berendt, M | 1 |
| Matiasek, LA | 1 |
| Luján Feliu-Pascual, A | 1 |
| Platt, SR | 1 |
| Chandler, KE | 1 |
2 trials available for piracetam and Canine Diseases
| Article | Year |
|---|---|
Pharmacokinetics of rectal levetiracetam as add-on treatment in dogs affected by cluster seizures or status epilepticus.
Topics: Administration, Rectal; Animals; Anticonvulsants; Dog Diseases; Dogs; Female; Levetiracetam; Male; P | 2018 |
A single-blinded phenobarbital-controlled trial of levetiracetam as mono-therapy in dogs with newly diagnosed epilepsy.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Female; Levetiracetam; Male; Phenobarbital; | 2016 |
6 other studies available for piracetam and Canine Diseases
| Article | Year |
|---|---|
Levetiracetam monotherapy for treatment of structural epilepsy in dogs: 19 cases (2010-2015).
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Follow-Up Studies; Levetiracetam; Piracetam; | 2017 |
Suspected Phenobarbital-Induced Pseudolymphoma in a Dog.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Levetiracetam; Male; Phenobarbital; Piraceta | 2017 |
Absence Seizures as a Feature of Juvenile Myoclonic Epilepsy in Rhodesian Ridgeback Dogs.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Electroencephalography; Epilepsies, Myoclonic; Female; | 2018 |
A serious adverse event secondary to rapid intravenous levetiracetam injection in a dog.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Drug Administration Schedule; Epinephrine; Fatal Outco | 2018 |
Assessment into the usage of levetiracetam in a canine epilepsy clinic.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Female; Levetiracetam; Male; Piracetam; Retr | 2015 |
The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs.
Topics: Animals; Anticonvulsants; Bromides; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Thera | 2008 |